Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
A
203400
vs
K
KOSPI 200
Over the past 12 months, Abion Inc has underperformed KOSPI 200, delivering a return of -76% compared to KOSPI 200's +116% growth.
Stocks Performance
203400 vs KOSPI 200
Performance Gap
203400 vs KOSPI 200
Performance By Year
203400 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Abion Inc
Glance View
Abion Inc is a South Korean biopharmaceutical company that develops and commercializes prescription medicines and drug candidates. Its core business is finding or designing new treatments, testing them, and turning the ones that work into products that doctors and patients can use. The company makes money in two main ways: by selling its own medicines through healthcare channels such as hospitals and pharmacies, and by earning licensing or collaboration income when it partners with other drug companies. In a business like this, the company often keeps some products for itself while sharing others with partners that help with development, manufacturing, or distribution. What makes Abion’s business model different is that it sits between research and the market. It is not a broad consumer health company; it depends on a pipeline of drug development, regulatory approval, and long-term value from successful medicines or licensed technology. That means its future is tied to whether it can turn scientific projects into approved products and durable commercial partnerships.